Edwards Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Edwards Lifesciences (EW).

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

17Buy

3Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$100Upside to Avg. PT+9.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Overweight	$110
Sep 11, 2026	BTIG	Marie Thibault	Maintained	Buy	$110
Jul 28, 2026	UBS	Patrick Wood	Assumes	Neutral→Buy	$110
Jul 24, 2026	Leerink Partners	Mike Kratky	Upgrade	Market Perform→Outperform	$87→$101
Jul 24, 2026	JP Morgan	Robbie Marcus	PT Raise	Overweight	$100→$105
Jul 24, 2026	Piper Sandler	Adam Maeder	PT Raise	Overweight	$100→$101
Jul 16, 2026	Truist Securities	Richard Newitter	PT Raise	Hold	$90→$95
Jul 15, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$100→$105
Jul 13, 2026	RBC Capital	Shagun Singh	PT Raise	Outperform	$100→$110
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$101→$110
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$93→$100
Jun 30, 2026	BTIG	Marie Thibault	PT Raise	Buy	$100→$110
Jun 16, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$100
Jun 2, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$97→$104
Apr 27, 2026	Barclays	Matt Miksic	PT Raise	Overweight	$104→$110
Apr 24, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$92→$93
Apr 24, 2026	Truist Securities	Richard Newitter	PT Raise	Hold	$89→$90
Apr 24, 2026	Canaccord Genuity	William Plovanic	PT Cut	Hold	$87→$85
Apr 24, 2026	BTIG	Marie Thibault	PT Raise	Buy	$98→$100
Apr 24, 2026	Baird	David Rescott	PT Raise	Neutral	$85→$87

Analyst Ratings News

PRO
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.

Benzinga Newsdesk

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.

Vandana Singh

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.

Benzinga Newsdesk

Edwards Lifesciences Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Edwards Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

People Also Watch

People Also Watch

Edwards Lifesciences Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Edwards Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

PROBTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

PROJP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

PROPiper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

PROTruist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95